Metrics based on PET/CT imaging can identify neuroendocrine tumor patients who may benefit from peptide receptor radionuclide therapy (PRRT) better than traditional imaging-based scoring measures, according to a study published in the September issue of The Journal of Nuclear Medicine.
Authors of a new study published Sept. 20 in the Journal of Nuclear Medicine argue that gallium-68 (68Ga) prostate-specific membrane antigen (PSMA)-11 PET/CT imaging can offer additional insight into bone metastases in prostate cancer patients and should be more widely used.
The Australian Nuclear Science and Technology Organization (ANSTO) confirmed it has shut down its Lucas Heights nuclear medicine facility following a “mechanical fault,” The Guardian reported. The shutdown puts an added strain on Australia’s already short supply of molybdenum-99 (Mo-99).
“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.
Using [68Ga]Ga-PSMA-11 PET/CT to monitor treatment response in prostate cancer patients can offer important lesion-based insights over prostate-specific membrane antigen (PSMA)-based monitoring, according to a new study published in EJNMMI Research.
In July, SHINE was one of three companies to receive $15 million in funding from the Department of Energy (DOE)’s National Nuclear Security Administration to bolster its production of molybdenum-99 (Mo-99).